WO2010096416A1 - Process for the reductive alkylation of normorphinans - Google Patents
Process for the reductive alkylation of normorphinans Download PDFInfo
- Publication number
- WO2010096416A1 WO2010096416A1 PCT/US2010/024372 US2010024372W WO2010096416A1 WO 2010096416 A1 WO2010096416 A1 WO 2010096416A1 US 2010024372 W US2010024372 W US 2010024372W WO 2010096416 A1 WO2010096416 A1 WO 2010096416A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chosen
- hydrogen
- formula
- group
- formic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- the present invention generally relates to a method for the synthesis of N-alkylated morphinans.
- the process provides a method for reducing an iminium salt formed from the reaction of a normorphinan and a carboxaldehyde,
- N-aikylated morphinans are important pharmaceuticals, typically used as analgesics, opiate agonists, and opiate antagonists. With the increasing use of these agents, a practical and effective method of preparation of these compounds is vital to synthesizing diverse N-alkyl substituted morphinans.
- N-alkylated morphinans have at least one of two primary limitations: (a) their dependence on a transition metal catalyst, and (b) the use of hydrogen gas as a source of hydrogen for the alkylation.
- Transition metal catalysts are expensive and toxic, which requires testing of the finished product to ensure that the final product does not contain more than a specified parts per million of the transition metal, Additionally, hydrogen gas is hazardous, and methods of synthesis typically employ high pressures.
- Some prior art methods have incorporated a borohydride to catalyze the reaction. It was desired to avoid this method because the side products are difficult to separate from the desired product, and the reactions may require lower temperatures, -20° to - 30° C, when a keto group is present.
- the present invention provides processes for the synthesis of N-alkylated morphinans from the corresponding normorphinan compounds.
- One aspect of the present invention encompasses a process for the preparation of an N- aikylated morphinan.
- the method comprises contacting a normorphinan comprising a secondary amine at position 17 with an alkylating agent comprising R 10 , wherein R 10 is selected from the group consisting of hydrocarbyi and substituted hydrocarbyl, a proton acceptor, and a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form the N-alkylated morphinan comprising NR 10 at position 17.
- R 10 is selected from the group consisting of hydrocarbyi and substituted hydrocarbyl, a proton acceptor, and a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form the N-alkylated morphinan comprising NR 10 at position 17.
- the current invention encompasses a process for the preparation of a compound comprising Formula (IiIa).
- the process comprises: (a) contacting a compound comprising Formuia (Ia) with an alkylating agent comprising R 10 in the presence of a proton acceptor to form a compound comprising Formula (Ha); and (b) contacting the compound comprising Formula (Ha) with a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form a compound comprising Formuia (Ilia) according to the following reaction scheme:
- R 2 , R 6 , and R 7 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and ⁇ - ⁇ 0R 11 ;
- R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and ⁇ - ⁇ 0R 11 ;
- R 5 is selected from the group consisting of hydrogen, and hydroxyl
- Rio is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl
- R 11 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxyl protecting group
- X is selected from the group consisting of oxygen and sulfur.
- the current invention encompasses a process for the preparation of a compound comprising Formula (lllb).
- the process comprises: (a) contacting a compound comprising Formula (Ib) with an alkylating agent comprising R 10 in the presence of a proton acceptor to form a compound comprising Formula (lib); and (b) contacting the compound comprising Formula (lib) with a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form a compound comprising Formula (IHb) according to the following reaction scheme:
- R 1 , R 2 , R 6 , R 7 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and ⁇ - ⁇ 0R 11 ;
- R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and HOR 11 ;
- R 5 is selected from the group consisting of hydrogen, and hydroxyl
- R 10 is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl
- R 11 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxy! protecting group.
- the present invention provides an efficient process for the production of N-alkylated morphinans in high yield,
- the process of the present invention avoids the use of toxic metal catalysts and dangerous hydrogen gas.
- the process of the invention may be conducted in a one-pot process, without isolation or purification of the intermediate products.
- One aspect of the present invention provides an efficient process for the production of N- alkylated morphinan compounds.
- the process comprises contacting a normorphinan comprising a secondary amine at position 17 with an alkylating agent comprising R 10 , wherein R 10 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl, a proton acceptor, and a reducing agent selected from the group consisting of formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof to form the N-alkylated morphinan comprising NR 10 at position 17.
- the normorphinan comprises any compound having a morphinan structure, in which the nitrogen at position 17 comprises a secondary amine. It will be understood by one skilled in the art that the "nor" compound may be produced by methods known in the art or purchased as a starting material.
- Non-limiting examples of normorphinans include norcodeine, normorphine, northebaine, nororipavine, noroxymorphone, nordihydromorphine, nordihydrocodeine, norhydrocodone, norhydromorphone, noroxycodone, nordextromethorphan, nordextrorphan, norlevomethorphan, norlevorphanol, norbuprenorphine, ⁇ oroxymomorphol, noroxycodol norsinomenine, nordihydrosinomenine, and combinations thereof.
- the normorphinan comprises noroxymorphone.
- the N-alkylated morphinan comprises any morphinan compound comprising a tertiary amine at position 17, wherein the amine at position 17 comprises a hydrocarbyl or substituted hydrocarbyl group.
- Suitable examples of N-alkylated morphinans include, but are not limited to codeine, morphine, thebaine, oripavine, oxymorphone, dihydromorphone, dihydrocodeine, hydrocodone, hydromorphone, oxycodone, oxycodeinone, naloxone, naltrexone, nalbuphine, naimefene, nalfurafine, morphinone, ethylmorphine, butorphanol, dextromethorphan, dextrorphan, levomethorphan, levorphanol, buprenorphine, sinomenine, dihydrosinomeni ⁇ e, and combinations thereof.
- the N-alkylated morphinans
- the R 10 group used to alkylate the nitrogen at position 17 is a hydrocarbyl or substituted hydrocarbyl group.
- the R 10 group may be an alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, or aryl group.
- the R 10 group may be methyl, cyciopropylmethyl, cyclobutylmethyl, or allyl.
- the process comprises formation of an intermediate compound comprising an iminium salt of the normorphinan compound, prior to the formation of the N-alkylated morphinan.
- the iminium salt serves as the substrate for reduction by formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, or combinations thereof, thereby forming the N-alkylated morphinan.
- the R 10 group of iminium salt may be an alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, or aryl group.
- the R 10 group may be methyl, cyclopropylmethyl, cyclobutylmethyl, or allyl.
- an N-alkylated morphinan comprising Formula (Ilia) is synthesized from a normorphinan comprising Formula (Ia).
- Reaction Scheme 1 depicts the production of the compound comprising Formula (Ilia) in accordance with one aspect of the present invention:
- R 2 , R e , and R 7 are independently selected from the group consisting of hydrogen, hydrocarby!, substituted hydrocarbyl, and ⁇ - ⁇ 0R 11 ;
- R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and ⁇ - ⁇ 0R 11 ;
- R 5 is selected from the group consisting of hydrogen, and hydroxyl
- R 10 is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl
- R 11 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxy! protecting group
- X is selected from the group consisting of oxygen and sulfur.
- R 3 , R 4 , R 6 , and R 7 are each hydrogen and X is oxygen.
- R 2 is preferably ⁇ - ⁇ OR 11 , wherein R 11 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxyl protecting group.
- R 5 is preferably hydroxy!.
- R 10 is preferably alky!, cycloalkyi, cycloalkylmethyl, ally!, or aryl; or more preferably methyl, ally!, cyclopropylmethyl, or cyclobutylmethyl.
- Representative compounds comprising Formula (Ilia) include, but are not limited to oxymorphone, dihydromorphone, hydrocodone, hydromorphone, oxycodone, oxycodeinone, naloxone, naltrexone, nalbuphine, nalmefene.
- an N-alkylated morphinan comprising Formula (HIb) is synthesized from a normorphinan comprising Formula (Ib).
- Reaction Scheme 2 depicts the production of the compound comprising Formula (I lib) in accordance with one aspect of the present invention: wherein:
- R 1 , R 2 , R 6 , R 7 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and ⁇ - ⁇ 0R 11 ;
- R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydrocarby!, substituted hydrocarbyl, halogen, and ⁇ - ⁇ 0R 11 ;
- R 6 is selected from the group consisting of hydrogen, and hydroxyl
- R 8 is selected from the group consisting of ⁇ 0, and hydroxyl
- R 10 is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl
- R 11 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxyl protecting group.
- Representative compounds comprising Formula (HIb) include, but are not limited to butorphanol, dextromethorphan, dextrorphan, levomethorphan, and levorphanol.
- the process of the invention commences with formation of a reaction mixture by combining the compound comprising Formulas (Ia) or (Ib) with an alkylating agent in the presence of a proton acceptor.
- alkylating agents are suitable for use in the process of the invention.
- the alkylating agent transfers an alkyl group from the alkylating agent to the nitrogen at position 17 of the normorphinan, and can therefore be thought of as any compound capable of transferring an alkyl group.
- the alkylating agent may be an aldehyde, having the general formula R 10 CHO, wherein R 10 may be hydrocarbyl or substituted hydrocarbyl.
- R 10 may be alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, aryl, cyclopropylmethyl, cyclobutylmethyl, or allyl.
- aldehydes examples include, but are not limited to alkyl-aldehydes such as methanal, ethanal, propanal, substituted propanal, butanal, substituted butanal, pentanal, substituted pentanal, hexanal, substituted hexanal, heptanal, substituted heptanal, octanal, substituted octanal, nonanal, substituted nonanal, decanal, substituted decanal, undecanal, substituted undecana!, dodecanal, substituted dodecanal, and substituted variations thereof; cycloalkyl- aldehydes such as cyclopropanecarboxaidehyde, cyclobutanecarboxaldehyde, cyclopentanecarboxaldehyde.
- alkyl-aldehydes such as methanal, ethanal, propanal, substituted propanal, butanal, substituted butanal
- the alkylating agent may be cyclopropanecarboxaidehyde or cyclobutanecarboxaldehyde.
- the mole-to-mole ratio of the compound comprising Formulas (Ia) or (Ib) to the alkylating agent can and will vary.
- the mole-to-mole ratio of the compound comprising Formulas (Ia) or (Ib) to the alkylating agent may range from about 1 :0.5 to about 1 :5.
- the ratio of compound comprising Formulas (Ia) or (Ib) to the alkylating agent may range from about 1 :1 to about 1 :2,
- the mole-to-mole ratio of the compound comprising Formulas (Ia) or (Ib) to the alkylating agent may be about 1 :1.4.
- the process of this invention additionally requires an agent for reducing the intermediate compound comprising Formula (Ha) or (lib).
- the reducing agent will be formic acid, an ester of formic acid, an alkali salt of formic acid, formamide, mixtures of formic acid and a salt of formic acid, or any combination thereof.
- Suitable esters of formic acid include but are not limited to methyl formate, ethyl formate, trimethyl formate, triethyl formate, methyl chloroformate, and the like.
- suitable alkali salts of formic acid include sodium formate, lithium formate, potassium formate, and cesium formate.
- the reducing agent may be formic acid.
- the mole-to-mole ratio of the compound comprising Formula (Ia) or (Ib) to the reducing agent will range from about 1 :1 to about 1 :20. In a preferred embodiment, the mole-to-mole ratio of the compound comprising Formula (Ia) or (Ib) to the reducing agent may range from about 1 : 10 to about 1 :15. In an exemplary embodiment, the mole-to-mole ratio of the compound comprising Formula (Ia) or (Ib) to the reducing agent may be about 1 :12.
- the process of this invention is also conducted in the presence of a proton acceptor.
- the proton acceptor has a pKa of between about 7 and about 13, preferably between about 8 and about 10.
- Representative proton acceptors that may be employed include, but are not limited to, borate salts (such as, for example, NaaBCb), di- and tri-basic phosphate salts (such as, for example, Na2HPU4 and Na3PO4), bicarbonate salts (such as, for example, NaHCOa 1 KHCO3, mixtures thereof, and the like), hydroxide salts (such as, for example, NaOH, KOH, mixtures thereof, and the like), carbonate salts (such as, for example, Na2CO3, K2CO3, mixtures thereof, and the like), alkyl amine bases (such as, for example, triethylamine, trimethylamine, tributylamine, diethylamine, and diisopropytethylamine), organic bases (such as,
- the proton acceptor may be triethylamine, trimethylamine, tributylamine, or pyridine, in an exemplary embodiment, the proton acceptor may be triethylamine.
- the mole-to-moie ratio of the compound comprising Formula (Ia) or (Ib) to the proton acceptor may range from about 1:1 to about 1 :20. In a preferred embodiment, the mole-to-mole ratio of the compound comprising Formula (ia) or (Ib) to the proton acceptor may range from about 1 :5 to about 1:10. In an exemplary embodiment, the mole-to-mote ratio of the compound comprising Formula (Ia) or (Ib) to the proton acceptor may be about 1 :8.
- the process of this invention is generally conducted in the presence of a solvent.
- the solvent may be a protic solvent, an aprotic solvent, or an organic solvent.
- Suitable examples of protic solvents include, but are not limited to, methanol, ethanol, isopropanol, n-propanol, isobutanol, n- butanol, s-butanol, f-butanol, formic acid, acetic acid, water, and combinations thereof.
- Non-limiting examples of suitable aprotic solvents include acetone, acetonitrile, diethoxymethane, N, N- dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylpropionamide, I.S-dimethyl-a ⁇ . ⁇ .e- tetrahydro-2 ⁇ 1H)-pyrimidinone (DMPU), 1 ,3-dimethyl-2-imidazolidinone (DMI), 1,2-dimethoxyethane (DME) 1 dimethoxymethane, bis(2-methoxyethyl)ether, N,N-dimethy!acetamide (DMAC), 1,4-dioxane, N-methyl-2- pyrrolidinone (NMP), ethyl acetate, ethyl formate, ethyl methyl ketone, formamide, hexachloroaceto ⁇ e, hexamethylphosphoramide, methyl acetate, N
- organic solvents include, but are not limited to, alkane and substituted alkane solvents ⁇ including cycloalkanes), aromatic hydrocarbons, esters, ethers, ketones, combinations thereof, and the like.
- Specific organic solvents that may be employed include, for example, acetonitrile, benzene, butyl acetate, f-butyl methylether, f-butyl methylketone, chlorobenzene, chloroform, chloromethane, cyclohexane, dichloromethane, dichloroethane, diethyl ether, ethyl acetate, diethylene glycol, fluorobenzene, heptane, hexane, isobutylmethylketone, isopropyl acetate, methylethylketone, methyltetrahydrofuran, penty!
- the solvent may be the protic solvent methanol.
- the weight ratio of the solvent to the compound comprising Formula (Ia) or (Ib) will range from about 0.5:1 to about 100:1. In preferred embodiments, the weight ratio of the solvent to the compound comprising Formula (Ia) or (Ib) may range from about 2:1 to about 5:1.
- reaction may be conducted at a temperature that ranges from about 20" C to about 120° C for a period of time that is sufficient to convert a substantial portion of the compound comprising Formula (!a) or (Ib) to the compound comprising Formula (Ilia) or (HIb).
- the reaction may be conducted at a temperature that ranges from about 40 ° C to about 100 ° C.
- the reaction may be conducted at a temperature that ranges from about 50 ° C to about 80 ° C.
- the reaction is allowed to proceed for a sufficient period of time until the reaction is complete, as determined by any method known to one skilled in the art, such as chromatography (e.g., HPLC).
- a "completed reaction” generally means that the reaction mixture contains a significantly diminished amount of the compound comprising Formula (Ia) or (Ib) and a significantly increased amount of the compound comprising Formula (Ilia) or (lllb) compared to the amounts of each present at the beginning of the reaction.
- the amount of the compound comprising Formula (Ia) of (Ib) remaining in the reaction mixture may be less than about 3%, and preferably less than about 1%,
- the yield of the compound comprising Formula (Ilia) or (IHb) can and will vary. Typically, the yield of the compound comprising Formula (Ilia) or (lllb) may be at least about 50%, In preferred embodiments of the invention, the yield of the compound comprising Formula (Ilia) or (lllb) may be at least about 65%,
- the reaction may also be performed in a one-pot process, whereby all reagents are added in one step to form the reaction mixture.
- the reaction mixture comprises the compound comprising Formula (Ia) or (Ib), the alkylating agent, the proton acceptor, and the reducing agent, as defined above.
- the one-pot process of the invention substantially eliminates the need to isolate or purify the intermediate compound comprising Formula (Ha) or (lib) and/or to manually add the reducing agent to the reaction mixture upon completion of the reaction with the alkylating reagent.
- any of the compounds comprising any of Formulas (I) or (II) may have a (-) or (+) orientation with respect to the rotation of polarized light, based on whether the starting material used is in the (-) or (+) opiate absolute form. More specifically, each chiral center may have an R or an S configuration.
- the compounds formed by the processes of the invention comprise morphinans. For purposes of illustration, the carbon atoms of a morphinan compound are numbered as diagrammed below.
- These morphinan compounds are recognized to have an alpha face and a beta face.
- Some compounds described herein may have at least three chiral centers, namely carbons C13, C14, and C9, provided that the C15 and C16 atoms are both on the alpha face of the molecule or both on the beta face of the molecule. Additionally, if the compound comprises a heterocyclic ring between carbons C4 and C5, C5 may also be a chiral center. At each chiral center, the stereochemistry at the carbon atom is independently R or S.
- Some compounds described herein may have at least four chiral centers, namely carbons C5, C9, C13, and C14. At each chiral center, the stereochemistry at the carbon atom is independently R or S.
- the configuration of carbons 5, 13, 14, and 9, respectively, may be RRRR, RRRS, RRSR 1 RSRR, SRRR 1 RRSS, RSSR, SSRR 1 SRRS, SRSR 1 RSRS, RSSS, SRSS, SSRS 1 SSSR, or SSSS, provided that the C15 and C16 atoms are both on the alpha face of the molecule or both on the beta face of the molecule.
- the nitrogen at position 17 may be either R or S, and depending on the R8 group chosen, C6 may also be a chiral center, with a stereochemistry of either R or S,
- Additional compounds described herein may have at least three chiral centers, namely carbons C13, C14, and C9.
- the stereochemistry at the carbon atom is independently R or S.
- the configuration of carbons 13, 14, and 9, respectively, may be RRR, RRS 1 RSR, SRR, SRS, SSR 1 RSS, or SSS, provided that the C15 and C16 atoms are both on the alpha face of the molecule or both on the beta face of the molecule.
- the nitrogen at position 17 may be either R or S, and depending on the R8 group chosen, C6 may also be a chiral center, with a stereochemistry of either R or S.
- the compounds described herein may have asymmetric centers.
- Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic form.
- Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chirai, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention.
- acyl denotes the moiety formed by removal of the hydroxy group from the group COOH of an organic carboxylic acid, e.g., RC(O) , wherein R is R 1 , R 1 O-, R 1 R 2 N-, or R 1 S-, R 1 is hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo, and R 2 is hydrogen, hydrocarbyi or substituted hydrocarbyl,
- acyioxy as used herein alone or as part of another group, denotes an acyl group as described above bonded through an oxygen linkage (O), e.g., RC(O)O- wherein R is as defined in connection with the term "acyl.”
- O oxygen linkage
- alkyl as used herein describes groups which are preferably lower alkyl containing from one to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, butyl, hexyl and the like.
- alkenyl as used herein describes groups which are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyi, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.
- alkynyl as used herein describes groups which are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.
- aromatic as used herein alone or as part of another group denotes optionally substituted homo- or heterocyclic aromatic groups. These aromatic groups are preferably monocyclic, bicyclic, or tricyclic groups containing from 6 to 14 atoms in the ring portion.
- aromatic encompasses the "aryi” and “heteroaryl” groups defined below.
- aryl or “Ar” as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl, Phenyi and substituted phenyl are the more preferred aryl.
- halogen or halo as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.
- heteroatom shall mean atoms other than carbon and hydrogen.
- heterocyclo or “heterocyclic” as used herein alone or as part of another group denote optionally substituted, fully saturated or unsaturated, monocyclic or bicyclic, aromatic or non- aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring.
- the heterocyclo group preferably has 1 or 2 oxygen atoms and/or 1 to 4 nitrogen atoms in the ring, and is bonded to the remainder of the molecule through a carbon or heteroatom.
- Exemplary heterocyclo groups include heteroaromatics as described below.
- substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, cyano, ketals, acetals, esters and ethers.
- heteroaryl as used herein alone or as part of another group denote optionally substituted aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring.
- the heteroaryl group preferably has 1 or 2 oxygen atoms and/or 1 to 4 nitrogen atoms in the ring, and is bonded to the remainder of the molecule through a carbon.
- hydrocarbon and “hydrocarbyi” as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to 20 carbon atoms.
- protecting group denotes a group capable of protecting an oxygen atom, wherein the protecting group may be removed, subsequent to the reaction for which protection is employed, without disturbing the remainder of the molecule.
- protecting groups include ethers ⁇ e.g., allyl, triphenylmethyl ⁇ trityl or Tr), p-methoxybenzyl (PMB), p-methoxyphenyl (PMP)), acetals (e.g., methoxymethyl (MOM), ⁇ -methoxyethoxymethyl (MEM), tetrahydropyranyl (THP), ethoxy ethyl (EE), methylthiomethyl (MTM), 2-methoxy-2-propyl (MOP), 2-tri methy lsily Ieth oxym ethyl (SEM)), esters (e.g., benzoate (Bz), allyl carbonate, 2,2,2-trichloroethyl carbonate
- TMS trimethylsiiyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- TPS triphenylsilyl
- TDMS t-buty Id imethy Is i Iy]
- TDPS t-butyldiphenylsilyl
- substituted hydrocarbyl moieties described herein are hydrocarbyl moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom.
- substituents include halogen, heterocyclo, alkoxy, aikenoxy, aryloxy, hydroxy, protected hydroxy, acyl, acyloxy, nitro, amino, amido, nitro, cya ⁇ o, ketals, acetals, esters and ethers.
- reaction mixture was removed from heating and a sample was taken. Approximateiy one drop of the reaction mixture was placed in 0.5 mL of 1% acetic acid, to prepare a sample for verification of reaction product. Upon sample analysis, it was shown to have a mass recovery of approximately 96%, Testing by high performance liquid chromatography (HPLC) revealed a naltrexone concentration of approximately 73% (w/w) of the sample, resulting in a yield of approximately 70%.
- HPLC high performance liquid chromatography
- the vial containing the reaction product was placed in a vacuum oven at ambient temperature under approximately 40 mm Hg vacuum pressure to further dry the sample. After approximateiy 19 hours in the vacuum oven, the sample was removed resulting in a tan solid weighing approximately 0.570 grams, which was subsequently verified to be naltrexone by HPLC assay.
- the mixture was added to the test tube containing the noroxymorphone and methanol mixture at a temperature of approximately 8 ° C.
- the combined reaction mixture was then heated by means of a J-Kem Personal Reaction Station (PRS) under an inert nitrogen environment.
- the temperature of the heating block was 74 ° C, but the internal temperature of the reaction mixture was measured at 72 ° C. Additionally, the temperature of the upper block was chilled to 0 ° C, and the reaction mixture was allowed to react.
- PRS J-Kem Personal Reaction Station
- reaction mixture was removed from heating and a sample was taken. Approximately one drop of the reaction mixture was placed in 0.5 mL of 1% acetic acid, to prepare a sample for verification of reaction product. Upon analysis, the sample was shown to have a mass recovery of approximately 108%. Testing by high performance liquid chromatography (HPLC) revealed a 6- ketonalbuphine concentration of approximately 77% (w/w) of the sample, resulting in a yield of approximately 83%.
- HPLC high performance liquid chromatography
- the vial containing the reaction product was placed in a vacuum oven at ambient temperature under approximately 40 mm Hg vacuum pressure to further dry the sample. After approximately 19 hours in the vacuum oven, the sample was removed resulting in a tan solid weighing approximately 0.666 grams, which was subsequently verified to be 6-ketonalbu ⁇ hine by HPLC assay.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL10704301T PL2398808T3 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
ES10704301.0T ES2440595T3 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
CA2752744A CA2752744A1 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
EP10704301.0A EP2398808B1 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
AU2010216150A AU2010216150B2 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
JP2011550321A JP5778042B2 (en) | 2009-02-17 | 2010-02-17 | Process for reductive alkylation of normorphinan |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15302109P | 2009-02-17 | 2009-02-17 | |
US61/153,021 | 2009-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010096416A1 true WO2010096416A1 (en) | 2010-08-26 |
Family
ID=42115354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/024372 WO2010096416A1 (en) | 2009-02-17 | 2010-02-17 | Process for the reductive alkylation of normorphinans |
Country Status (8)
Country | Link |
---|---|
US (1) | US8431701B2 (en) |
EP (1) | EP2398808B1 (en) |
JP (2) | JP5778042B2 (en) |
AU (1) | AU2010216150B2 (en) |
CA (1) | CA2752744A1 (en) |
ES (1) | ES2440595T3 (en) |
PL (1) | PL2398808T3 (en) |
WO (1) | WO2010096416A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962841B2 (en) * | 2007-06-29 | 2015-02-24 | Brock University | Methods for one-pot N-demethylation/N-functionalization of morphine and tropane alkaloids |
CN103002882B (en) | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | The preparation of the granule not containing activating agent and the tablet comprising it |
EA201291211A1 (en) | 2010-05-10 | 2013-05-30 | Эро-Селтик С.А. | PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
FR2984320B1 (en) * | 2011-12-20 | 2013-11-29 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID |
CN103387539A (en) * | 2012-05-08 | 2013-11-13 | 长沙理工大学 | Synthesis of 4-benzyloxy-17-acetyl morphinan-6-one |
CN103387579A (en) * | 2012-05-08 | 2013-11-13 | 长沙理工大学 | Synthesis of 4-benzyloxy-17-benzenesulfonylmorphinan-6-one |
PL3049378T3 (en) | 2013-09-25 | 2019-06-28 | SpecGx LLC | Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit |
KR102194174B1 (en) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
US9701687B2 (en) | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
US9701688B2 (en) | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
CN109096190B (en) * | 2017-06-21 | 2021-07-02 | 中国医学科学院药物研究所 | Sinomenine derivative, preparation method, application and pharmaceutical composition thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006035195A1 (en) * | 2004-09-30 | 2006-04-06 | Johnson Matthey Public Limited Company | Preparation of opiate analgesics by reductive alkylation |
WO2009012005A1 (en) * | 2007-07-17 | 2009-01-22 | Mallinckrodt Inc. | Preparation of n-alkylated opiates by reductive amination |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2578787A (en) * | 1949-04-09 | 1951-12-18 | Rohm & Haas | Reduction of enamines |
TW200736218A (en) * | 2006-01-18 | 2007-10-01 | Otsuka Chemical Co Ltd | Method for producing tertiary amines |
EP2032579A2 (en) | 2006-05-25 | 2009-03-11 | Alpharma (Bermuda) Investments Ltd | Process useful in the preparation of morphinan antagonists |
AU2009300392B2 (en) * | 2008-09-30 | 2014-10-23 | SpecGx LLC | Processes for the selective amination of ketomorphinans |
-
2010
- 2010-02-17 EP EP10704301.0A patent/EP2398808B1/en not_active Not-in-force
- 2010-02-17 ES ES10704301.0T patent/ES2440595T3/en active Active
- 2010-02-17 CA CA2752744A patent/CA2752744A1/en not_active Abandoned
- 2010-02-17 US US12/706,909 patent/US8431701B2/en active Active
- 2010-02-17 JP JP2011550321A patent/JP5778042B2/en not_active Expired - Fee Related
- 2010-02-17 WO PCT/US2010/024372 patent/WO2010096416A1/en active Application Filing
- 2010-02-17 PL PL10704301T patent/PL2398808T3/en unknown
- 2010-02-17 AU AU2010216150A patent/AU2010216150B2/en not_active Ceased
-
2015
- 2015-05-20 JP JP2015102372A patent/JP2015180661A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006035195A1 (en) * | 2004-09-30 | 2006-04-06 | Johnson Matthey Public Limited Company | Preparation of opiate analgesics by reductive alkylation |
WO2009012005A1 (en) * | 2007-07-17 | 2009-01-22 | Mallinckrodt Inc. | Preparation of n-alkylated opiates by reductive amination |
Non-Patent Citations (1)
Title |
---|
T.W. GREENE AND P.G.M. WUTS,: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
Also Published As
Publication number | Publication date |
---|---|
JP5778042B2 (en) | 2015-09-16 |
AU2010216150B2 (en) | 2015-05-14 |
US8431701B2 (en) | 2013-04-30 |
JP2012518013A (en) | 2012-08-09 |
AU2010216150A1 (en) | 2011-09-08 |
EP2398808B1 (en) | 2013-11-20 |
CA2752744A1 (en) | 2010-08-26 |
JP2015180661A (en) | 2015-10-15 |
ES2440595T3 (en) | 2014-01-29 |
US20100210843A1 (en) | 2010-08-19 |
EP2398808A1 (en) | 2011-12-28 |
PL2398808T3 (en) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8431701B2 (en) | Process for the reductive alkylation of normorphinans | |
JP5688974B2 (en) | Processes and compounds for the production of (+)-opiates | |
US8080661B2 (en) | Processes for the synthesis of tertiary amines | |
EP2222679B1 (en) | Process for the preparation of buprenorphine and derivatives of buprenorphine | |
CA2806596A1 (en) | N-demethylation of 6-keto morphinans | |
EP2601195B1 (en) | Tandem process for preparing n-alkyl morphinans | |
US9012468B2 (en) | One pot process for producing 6-hydroxyl nal-opiate | |
AU2014348256B2 (en) | Preparation of normorphinans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10704301 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010216150 Country of ref document: AU Ref document number: 2752744 Country of ref document: CA Ref document number: 2011550321 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010704301 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010216150 Country of ref document: AU Date of ref document: 20100217 Kind code of ref document: A |